Page 21

REGENERATIVE MEDICINE: ENERGISING TECHNOLOGY EVOLUTION TOWARDS FUTURE MEDICINE

Research and Development (AMED), and highly organised safety and quality standards are needed in addition to post-market surveillance. In a recent report by Frost & Sullivan12, principal industry interaction strategies depicting the key players across industries in Japan are illustrated, listing the principal foreign companies targeting Japan, as well as the Japanese companies awaiting opportunities in the space of regenerative medicine. Similarly, in the US, the Georgia Research Alliance and the Georgia Institute of Technology are propelling the National Cell Manufacturing Consortium, an industry–academic–government partnership responsible for the National Roadmap for Advanced Cell Manufacturing, sponsored by the National Institute of Standards and Technology (NIST). In Europe, the TERMIS-Europe Industry Committee intended to address the two main critical issues in the clinical/commercial translation of advanced therapeutic medicinal

products by propelling entrepreneurial expansion of disruptive innovations, and discussing new pathways for regulatory market approval. How companies are competing to leverage the optimal niche

In the competitive landscape across regenerative medicine, Fujifilm Corporation represents a paramount instance of technology synergy and business strategy. Through the consolidation of the group after the acquisitions of CDI and J-TEC, Fujifilm is focused on expanding regenerative medicine product line by combining its proprietary extracellular matrix with somatic and stem cells products from JTE; regenerating organs via iPSCs; and expanding drug discovery support by conjugating extracellular matrix where iPSCs can grow and differentiate for clinical trials. Osiris Therapeutics has advanced stem cell technology to exploit the natural abilities of cellular matrices to promote the

continued

body’s natural healing through the MSC Primer platform, receiving approval for remestemcel-L in Canada and New Zealand for the treatment of graft-versus-host disease, the first approved stem cell drug. After granting two patents from the Japanese Patent Office addressing 3D methods for expanding placental and adipose cells, Pluristem has partnered with a venture company derived from the University of Tokyo to advance the treatment of ischaemic diseases. Focused on large degenerative disease markets, BioTime expects to reach a broader market facing multiple near-term clinical milestones worldwide. Conclusion Why focus on regenerative medicine?

In the coming years, regenerative medicine is expected to experience a great revolution in terms of products launched and customer niches penetrated. Timelines and costs associated with the

Figure 1. Focus area 1: Technology synergy – how to propel research and development activities towards future medicine.

european INDUSTRIAL PHARMACY December 2016

• Issue 31

21

european Industrial Pharmacy Issue 31 (December 2016)  

European Industrial Pharmacy is the electronic journal of the European Industrial Pharmacists Group (EIPG). The journal contains articles, n...

european Industrial Pharmacy Issue 31 (December 2016)  

European Industrial Pharmacy is the electronic journal of the European Industrial Pharmacists Group (EIPG). The journal contains articles, n...

Advertisement